HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
All
Press Release
News Update
Quarterly update
Total
72
72
Press Release
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
2024-01-30
71
Press Release
NeoImmuneTech Welcomes a New President for its development and business
2024-01-15
70
Press Release
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
2023-12-12
69
Press Release
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2023-11-20
68
Press Release
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
2023-10-04
67
Press Release
NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
2023-07-26
66
Press Release
NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)
2023-01-03
65
Press Release
New evidence of NeoImmuneTech’s NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors
2022-11-14
64
Press Release
NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
2022-11-04
63
Press Release
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
2022-10-06
1
2
3
4
5
>
>>
Search